The earnings call highlighted several positive developments, including strategic hires, promising BOT/BAL data, and multiple capital proposals which could strengthen the company's financial position. However, financial metrics such as a decreased cash balance and lower revenue compared to the previous year, alongside ongoing regulatory challenges, present notable challenges. The overall sentiment is cautiously optimistic as the highlights and lowlights are balanced.

Company Guidance

During Agenus Inc.'s First Quarter 2025 Earnings Conference Call, the company outlined several strategic priorities, focusing on their innovative BOT/BAL data, operational efficiencies, and impending transactions to enhance financial strength. They aim to reduce operational cash burn to below $50 million annually by the second half of 2025. The company's financials for the first quarter showcased a cash balance of $18.5 million, a reduction from $40.4 million at the end of 2024, with a net loss of $26.4 million or $1.03 per share. Revenue was reported at $24.1 million, primarily from non-cash royalty revenue. Agenus has received four transaction proposals, including a potential Emeryville facility sale and two BOT/BAL licensing deals, aimed to bolster their balance sheet. The call emphasized the wide-reaching potential of BOT/BAL in treating cold tumors, with promising data from recent studies, and discussed the evolving regulatory landscape that could expedite therapy approvals.

Operational Efficiency Goals

Agenus is on track to reduce its operational cash burn to below $50 million annualized in the second half of 2025.

New Leadership and Strategic Hire

Dr. Richard Goldberg, a GI-Oncology expert, joined as Chief Development Officer to advance regulatory filings in metastatic colorectal cancer and other tumor types.

Promising BOT/BAL Data

New BOT/BAL data shows durable responses in cold tumors, including MSS colorectal cancer, with deep and durable disease control demonstrated in heavily pre-treated liver cancer patients.

Strategic Capital Proposals

Agenus received four formal transaction proposals, including the sale of the Emeryville facility, a significant equity investment at a premium, and two licensing deals for BOT/BAL.

Regulatory Environment Shift

Changes in FDA policies may favor rapid approval of transformative therapies, aligning with Agenus' goals for BOT/BAL's accelerated approval.

Agenus (AGEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AGEN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	2.20 / -	-3.08	―	―	―
Aug 11, 2025	2025 (Q2)	2.42 / -1.00	-2.52	60.32% (+1.52)	―	―
May 12, 2025	2025 (Q1)	-1.65 / -1.03	-3.04	66.12% (+2.01)	―
Mar 11, 2025	2024 (Q4)	-2.54 / -2.04	-2.6	21.54% (+0.56)	―
Nov 12, 2024	2024 (Q3)	-2.31 / -3.08	-3.2	3.75% (+0.12)	―
Aug 08, 2024	2024 (Q2)	-1.07 / -2.52	-4	37.00% (+1.48)	―
May 07, 2024	2024 (Q1)	-3.21 / -3.04	-4.4	30.91% (+1.36)	―
Mar 14, 2024	2023 (Q4)	-1.07 / -2.60	-4.71	44.80% (+2.11)	―
Nov 07, 2023	2023 (Q3)	-3.90 / -3.20	-3.729	14.19% (+0.53)	―
Aug 08, 2023	2023 (Q2)	-3.90 / -4.00	-3.336	-19.90% (-0.66)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AGEN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$4.80	$4.27	-11.04%
May 12, 2025	$2.91	$3.50	+20.27%
Mar 11, 2025	$2.15	$2.05	-4.65%
Nov 12, 2024	$3.90	$3.10	-20.51%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Agenus (AGEN) report earnings?

Agenus (AGEN) is schdueled to report earning on Nov 11, 2025, Before Open (Confirmed).

What is Agenus (AGEN) earnings time?

Agenus (AGEN) earnings time is at Nov 11, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AGEN EPS forecast?

AGEN EPS forecast for the fiscal quarter 2025 (Q3) is 2.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing